BRN Discussion Ongoing

[Chimi]

ich bin auch aus Bayern

Mittelfranken

 

[MaxwellAnne]

Deutsche Medien berichten Kanzler Scholz hat stark und souverän mit Putin gesprochen, es gibt auch schon teilweisen Rückzug von Putin, Biden jedoch sagt es könnte jederzeit eskalieren, ich als Deutsche denke es ist schwierig zu beurteilen was USA und Russland für Kämpfe ausführen, ich denke doch es hat sich derzeit ein klein wenig beruhigt und wir können nur hoffen, dass es so weitergeht, wer von uns will schon Krieg, die Börse hat auch heute positiv darauf reagiert

Any chance of a translate button @zeebot ?

 

[Diogenese]

Thanks, FF, we are all in the same boat. Medical ethics is a minefield. I don't want to buy shares in a company that sells hope by supplying drugs to patients who the FDA consider to be so hopeless, all other treatments having failed, that they can go onto the company's clinical trial. ie read the special conditions of each clinical trial and decide for yourself what the FDA is telling you.

I look forward to the increased use of AI, including Akida, to help design the new drugs and treatments, that aren't just magic bullets shot into the dark.

Hi Iseki,

I'm sure you are not advocating throwing the baby out with the bath water.

There are many cancer drug research companies which perfrom ethical research, provided your philosophy allows mouse tests.

One particularly promising avenue of research is the use of cancer antigens to specifically target cancerous cells.

One such Australian company has developed such an antigen which, on its own, can inhibit the reproduction of cancer cells by penetrating the cell membrane and interrupting the cell's DNA damage repair mechanism. The antibody has the ability to cross the blood-brain barrier to attack difficult to treat glioblastomas. In addition, the antibody can act as a vector to carry anticancer drugs and radiation targets specifically into cancer cells.

These characteristics mean that the use of these antibodies has the potential to signiicantly reduce the adverse side effects of chemotherapy and reduce the collateral damage caused by conventional chemotherapy and radiation treatment.

Just as with COVID or any other drug, it is necessary that the drugs undergo clinical trials on human volunteers. Once the drugs have been proved to be safe and effective on lab mice, the drugs need to be tested on healthy subjects to determine the degree of toxicity, and then they need to be tested on cancer patients to determine their effectiveness.

The drug development companies need to have insurance, and the insurance companies will, as is their nature, seek to limit their potential liability. I have not read the FDA conditions, but I imagine the insurance liability is, at least in part, responsible for some of the exclusions.

There is hope for effective treatment in the foreseeable future.

Hey Diogenese (aka Barrel),

I was just looking at this tutorial at the May 2019 Embedded Vision Summit. Yoshio Sato, Senior Product Marketing Manager in the Industrial Business Unit at Renesas, says at the 22 minute mark that they are looking for partners to work with Renasas on the Roadmap for DRP to enhance embedded AI inference capabilities.

I guess this is where BrainChip fits in, or could fit in.


View attachment 1147

Hi Bravo,

Well possibly that's where the BrainChip/Renesas hook-up started.

I would think that incorporating Akida in the Renesas DRP would have involved a major redesign of their DRP.

This is from my files, but I don't have a link, but you should be able to find it on the Renesas site:

 

[Slade]

Hi Iseki,

I'm sure you are not advocating throwing the baby out with the bath water.

There are many cancer drug research companies which perfrom ethical research, provided your philosophy allows mouse tests.

One particularly promising avenue of research is the use of cancer antigens to specifically target cancerous cells.

One such Australian company has developed such an antigen which, on its own, can inhibit the reproduction of cancer cells by penetrating the cell membrane and interrupting the cell's DNA damage repair mechanism. The antibody has the ability to cross the blood-brain barrier to attack difficult to treat glioblastomas. In addition, the antibody can act as a vector to carry anticancer drugs and radiation targets specifically into cancer cells.

These characteristics mean that the use of these antibodies has the potential to signiicantly reduce the adverse side effects of chemotherapy and reduce the collateral damage caused by conventional chemotherapy and radiation treatment.

Just as with COVID or any other drug, it is necessary that the drugs undergo clinical trials on human volunteers. Once the drugs have been proved to be safe and effective on lab mice, the drugs need to be tested on healthy subjects to determine the degree of toxicity, and then they need to be tested on cancer patients to determine their effectiveness.

The drug development companies need to have insurance, and the insurance companies will, as is their nature, seek to limit their potential liability. I have not read the FDA conditions, but I imagine the insurance liability is, at least in part, responsible for some of the exclusions.

There is hope for effective treatment in the foreseeable future.

Hi Bravo,

Well possibly that's where the BrainChip/Renesas hook-up started.

I would think that incorporating Akida in the Renesas DRP would have involved a major redesign of their DRP.

This is from my files, but I don't have a link, but you should be able to find it on the Renesas site:


View attachment 1154

Hello Diogenes, the Renesas presentation last night was over my head but you might be able to find something interesting in the guys PPT.

 

[Slade]

The guy made a point of highlighting that AI inferencing is a new addition.

 

[Techinvestor17]

Slightly off the current topics but I have been going back through the historical announcements to see if there's any old leads worth following up and did end up finding a few.
- Veritone
- Softcyprum
- Safran, there is a recent video of theirs I'm sure was already posted but for anyone that missed it its here https://www.safran-group.com/videos/vision-innovation-automate-visual-inspection

Additionally there are two leads I never could quite close out
1. what happened to the "Game outcome" product that we had being developed the GPI that were taken over by Angel Group.
2. what eventuated from the official information request that was made to Lockport in regards to the SN tech audit.

The company updates appear to just stop referring to them rather than actually close out the issues.

If anyone knows any more I would appreciate the insight. I realize question 1 is probably a bit contentious seeing is that it was the milestone payment that effectively vested LDN a substantial amount of shares and doesn't appear to have materialized into anything substantial.

 

[Diogenese]

Hi Iseki,

I'm sure you are not advocating throwing the baby out with the bath water.

There are many cancer drug research companies which perfrom ethical research, provided your philosophy allows mouse tests.

One particularly promising avenue of research is the use of cancer antigens to specifically target cancerous cells.

One such Australian company has developed such an antigen which, on its own, can inhibit the reproduction of cancer cells by penetrating the cell membrane and interrupting the cell's DNA damage repair mechanism. The antibody has the ability to cross the blood-brain barrier to attack difficult to treat glioblastomas. In addition, the antibody can act as a vector to carry anticancer drugs and radiation targets specifically into cancer cells.

These characteristics mean that the use of these antibodies has the potential to signiicantly reduce the adverse side effects of chemotherapy and reduce the collateral damage caused by conventional chemotherapy and radiation treatment.

Just as with COVID or any other drug, it is necessary that the drugs undergo clinical trials on human volunteers. Once the drugs have been proved to be safe and effective on lab mice, the drugs need to be tested on healthy subjects to determine the degree of toxicity, and then they need to be tested on cancer patients to determine their effectiveness.

The drug development companies need to have insurance, and the insurance companies will, as is their nature, seek to limit their potential liability. I have not read the FDA conditions, but I imagine the insurance liability is, at least in part, responsible for some of the exclusions.

There is hope for effective treatment in the foreseeable future.

Hi Bravo,

Well possibly that's where the BrainChip/Renesas hook-up started.

I would think that incorporating Akida in the Renesas DRP would have involved a major redesign of their DRP.

This is from my files, but I don't have a link, but you should be able to find it on the Renesas site:


View attachment 1154

I've been having trouble with latency on my mainframe, and as a result two separate posts ended up being blended.

Hi Bravo,

As I was about to say, looking at Figure 3, I'm not sure Akida would be compatible with the Renesas DRP because of the differing design philosophies, but I don't really know much about the Renesas DRP.

Hey Diogenese (aka Barrel),

I was just looking at this tutorial at the May 2019 Embedded Vision Summit. Yoshio Sato, Senior Product Marketing Manager in the Industrial Business Unit at Renesas, says at the 22 minute mark that they are looking for partners to work with Renasas on the Roadmap for DRP to enhance embedded AI inference capabilities.

I guess this is where BrainChip fits in, or could fit in.


View attachment 1147

Slightly off the current topics but I have been going back through the historical announcements to see if there's any old leads worth following up and did end up finding a few.
- Veritone
- Softcyprum
- Safran, there is a recent video of theirs I'm sure was already posted but for anyone that missed it its here https://www.safran-group.com/videos/vision-innovation-automate-visual-inspection

Additionally there are two leads I never could quite close out
1. what happened to the "Game outcome" product that we had being developed the GPI that were taken over by Angel Group.
2. what eventuated from the official information request that was made to Lockport in regards to the SN tech audit.

The company updates appear to just stop referring to them rather than actually close out the issues.

If anyone knows any more I would appreciate the insight. I realize question 1 is probably a bit contentious seeing is that it was the milestone payment that effectively vested LDN a substantial amount of shares and doesn't appear to have materialized into anything substantial.

I think that the company that took over has their own chip verification system:
https://www.casinointernational-online.com/gpi/

 

[wilzy123]

Please include translation too so us English only speakers do not miss out on your insights

The only German I can (kind of) remember from school is “Ich bin auslander und spreche nicht gut Deutsch”

And also schraubenschlüßel (spanner) - one of my all time favourite words to say

The internet can help you out here...

Google Translate

Google's service, offered free of charge, instantly translates words, phrases, and web pages between English and over 100 other languages.

translate.google.com

 

[White Horse]

I would only guess that is where Sean, Rob and Jerome would step in to educate Dr Dunbar.

Hi Dhm,
Correct, I fired of an email straight after watching the presentation.

 

[Potato]

https://www.benzinga.com/pressrelea...esents-at-international-investment-forum-2022

Not sure if this has been posted yet but Sean is presenting tomorrow. Online registration is on that page via the above link.

It's good to see him getting out there and promoting the product. Huge confidence booster for investors.

 

[Justchilln]

View attachment 1167

https://www.benzinga.com/pressrelea...esents-at-international-investment-forum-2022

Not sure if this has been posted yet but Sean is presenting tomorrow. Online registration is on that page via the above link.

It's good to see him getting out there and promoting the product. Huge confidence booster for investors.

is this tomorrow 7.30 pm Sydney time?

 

[Potato]

is this tomorrow 7.30 pm Sydney time?

Says 2am Perth time, so thats 5am Sydney?

 

[Justchilln]

Oh dang that would disrupt my beauty sleep somewhat…
Can someone record pretty please?

 

[Quatrojos]

Brazil, si?

Telstar - Customized Thermal Vacuum Chambers

Our dedicated vacuum systems are designed to achieve Ultra High Vacuum levels even under typical gas loads emanating from Devices Under Test.

www.telstar.com

 

[Quatrojos]

Brazil, si?

Telstar - Customized Thermal Vacuum Chambers

Our dedicated vacuum systems are designed to achieve Ultra High Vacuum levels even under typical gas loads emanating from Devices Under Test.

www.telstar.com

View attachment 1172

 

[Quatrojos]

View attachment 1173

Telstar is heavily into refrigeration/cooling systems...

Equipment for Life Science Laboratories & Hospitals - Telstar®

www.telstar.com

 

[Quatrojos]

Telstar is heavily into refrigeration/cooling systems...

Equipment for Life Science Laboratories & Hospitals - Telstar®

www.telstar.com

Also calibration...

Calibration Services - Telstar®

www.telstar.com

 

[Quatrojos]

Also calibration...

Calibration Services - Telstar®

www.telstar.com

These guys seem to fit like a glove...

 

[Quatrojos]

azbil Group - Telstar®

www.telstar.com

And a connection with Japan. This is all lining up...

 

[Quatrojos]

azbil Group - Telstar®

www.telstar.com

And a connection with Japan. This is all lining up...

トップ EN | Azbil Corporation

Information regarding the of Azbil Corporation Advanced Automation company (Former Yamatake Corporation). We solve problems at factories, plants, and a variety of other production sites by providing products, solutions, instrumentation, engineering and maintenance services to support optimal...

www.azbil.com

...possibly another suburb of El Dorado...